downgrad equal-weight
share effect price
downgrad overweight equal-weight share
close pt remain share
outperform major pharma trade
premium peer close histor peak lilli
fulli insul potenti covid-rel busi
downgrad share ow ew three reason first
stock approach pt share close pt second
price-to-earnings premium group spike close histor peak
third although lilli manag reiter guidanc march see
risk sales/earn due unemploy risk us commerci
share outperform believ key factor includ higher
percentag revenu peer outpati drug face less short-
term covid-rel disrupt hospit physician-administ drug
lilli re-affirmed guidanc press releas wherea
pharma compani highlight covid-rel uncertainti lilli
less depend upon new drug launch certain peer lilli seen
high-qual durabl growth compani less long-term patent exposur
peer
new equal weight thesi lilli solid long-term growth pipelin
prospect balanc rel high valuat project long-term mid-
singl digit revenu low doubl digit ep growth lilli diabet franchis
enhanc pipelin candid includ high-dos trulic
novel drug tirzepatid see alzheim candid high risk high
reward stock high multipl reflect prospect view
valuat explain includ premium peer pt remain
ep lilli price-to-earnings rel major pharma current
premium close high end histor peak exhibit
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
lilli resili face covid note compani
fulli insul given us commerci exposur estim lilli
us revenu total vs
biopharma exclud establish product note gener
higher percentag us sale lilli medicar part primarili infus
oncolog drug potenti issu rise unemploy could increas
percentag peopl non-commerci coverag includ medicaid
although govern could pass addit fund temporarili bridg
gap unemploy unclear us return
could equal-weight rate wrong share could continu
outperform result meet/exce expect lilli result
outshin peer covid crisi pipelin expect rise
execut encourag share could under-perform result fall
short expect fallout unemploy pressur us
commerci sale pipelin disappoint occur
near-term catalyst potenti fda accept aducanumab file
alzheim could impact percept fda bar novel
alzheim therapi result guidanc updat april
trulic high-dos phase data ada june virtual plan
compar cross-trial ozemp
exhibit price-to-earnings rel major pharma
price-to-earnings rel major pharma
base case ep premium peer averag due lilli better
growth prospect ep compound-annual-growth-rate vs group average lower exposur patent
equal-weight share see
compani robust prospectsbalanc
ep note risk
modest covid-rel impact growth
pipelin newsow diabet
transact enhanc long-term growth
consensu
view descript risk reward theme
financi key pipelin agent
competit pressur covid-rel
factor drive earn
impact wors expect
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
earn forecast alzheim
newsow surpris upsid
growth driver upsid yield ep
forecast alzheim surpris
upsid investor enthusiasm
impact nancial result immateri
solid growth prospect balanc high
growth low doubl digit long-term ep
growth anticip margin expans
expect posit newsow tirzepatid ph
diabet candid rule
side effect risk sinc drug includ
novel mechan gip alzheim
aducanumab -amyloid antibodi ling decis
fda
earn releas guidanc updat
trulic high-dos data ada june
virtual posit top-line
quarterli result nancial guidanc updat
jardianc taltz verzenio
alzheim
china india
view explan region hierarchi
research highest favor quintil
upsid risk nancial result
tirzepatid diabet alzheim s-relat
newsow compet product disappoint
tirzepatid alzheim compet drug
surpris upsid new litig risk
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
